Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? The single pill of amlodipine/atorvastatin

Figures & data

Figure 1 Rates of hypertension prevalence, treatment, and control in eight countries.

Figure 2 Blood pressure and lipid targets for the GEMINI and CAPABLE trials, based on JNC VI blood pressure and NCEP ATP lipid recommendations.

Figure 3 Percentage of GEMINI patients at blood pressure, lipid, or combined targets by cardiovascular disease risk category (NCEP ATP I to III risk categories) at baseline.

• CV Risk Group I – Hypertension and dyslipidemia

• CV Risk Group II – Hypertension and dyslipidemia and presence of at least one other CVD risk factor (ie, men ≥ 45 years, women ≥ 55 years, premature CHD in first-degree relative, current smoker, HDL-C <40 mg/dL)

• CV Risk Group III – Hypertension and dyslipidemia with CHD or CHD equivalents (ie, diabetes mellitus, any atherosclerotic disease)

Figure 4 Blood pressure and lipid targets for the JEWEL I and II studies, based on country specific recommendations.

Figure 5 Proportions of patients meeting either blood pressure or lipid targets and both in JEWEL I and II studies after 16 weeks of amlodipine/atorvastatin (Caduet) therapy in 2219 patients.